Changjiang Commercial Daily News ● Changjiang Commercial Daily reporter Wang Jing
NovemberOn the evening of the 8th, Baiyang Pharmaceutical (301015.SZ) issued an announcement saying that in order to further deepen cooperation, promote the integration and coordinated development of resource, the company and the worlds leading radioactive surgery robot enterprise Zap Medical System, LTD. Signed an investment agreement to participate in the subscription subscriptionIts E -series priority shares are issued.At the same time, Baiyang Pharmaceutical and Zap Surgical Systems, Inc. (hereinafter referred to as "ZAP") intend to sign a commercialization agreement and undertake ZAP core product head and neck radiotherapy system ZAP-X?X ") and related accessories exclusive commercial operation rights in Mainland China and Hong Kong and Macau.
Public information shows that ZAP-X common indications include listening neuroma, meningioma, pituitary tumor and other brains and dynamic venous vascular malformations,Other brain diseases such as trigeminal neuralgia.
The company said that the company is optimistic about the development potential of the future ZAP in the precise radiotherapy track. Under the coordination of the groups ecological innovation, it will be full -chain from technology research and development, large -scale production, marketing and other full chains.Promote the landing and application of ZAP-X to provide more advanced and more effective treatment plans for patients around the world.
The reporter from the Yangtze River Business Daily noticed that public information shows that Baiyang Medicine is in the pharmaceutical circulation industry and benefits from the influenceThe companys core brand operation business has maintained high prosperity.
From January to September 2024, Baiyang Pharmaceuticals revenue achieved revenue of 6.144 billion yuan, an increase of 2.65%year -on -year; net profit was 641 million yuan, a year -on -year increase of 17.42%.
The preferred shares of the ZAPE series
On the evening of November 8, Baiyang Medicine issued an announcement, saying,In order to further deepen cooperation and promote resource integration and coordinated development, the company signed an investment agreement with Zap Medical System and LTD. to participate in the subscription of E -series preferred shares issued.
As early as July this year, Baiyang Health and the target company signed an agreement to subscribe for $ 15 million in the target company with their own funds.Some convertible bills are converted into the E-2 series of preferred shares issued by the target company; Baiyang Chengda plans to subscribe for the E-1 series of preferred shares issued by the target company with its own funds.
After the transaction was completed, the cumulative amount of Baiyang Chengda and Baiyang Health Investment target company was 50 million US dollars, and 8.22%of Baiyang Health holding the target company.Yang Chengda holds 10.92%of the equity of the target company, and the company indirectly holds 19.14%of the equity of the target company.
At the same time, Baiyang Pharmaceutical and ZAP intend to sign a commercialization agreement to undertake the exclusive commercialization of ZAP-X and related accessories of the ZAP core product head and neck radiotherapy system ZAP-X and related accessoriesOperating rights.
It is reported that ZAP is a global innovative research and development company born in Silicon Valley, the founder and CEO John R. Adler, the founder of the companys company,The inventor is also the inventor of the radiological system of radiotherapy equipment.
Announcement shows that ZAP-X is a radiological surgical robot developed by intracranial, neck physical malignant tumors and lesions.Radiation therapy equipment.At present, ZAP-X has obtained the listing of many countries and regions around the world and other countries and regions in the United States, the European Union, Japan, India, and was approved by the Innovation Products of the State Drug Administration in June 2023 to officially enter China.Common indications for this product include brain tumors such as hearing neuroma, meningoma, and pituitary tumor, and other brain diseases such as carotid vascular malformations and trigeminal neuralgia.
It is worth noting that since this year, Baiyang Medicine has continuously expanded its asset expansion business.
On May 20 this year, Baiyang Pharmaceutical issued an announcement saying that it is planned to acquire Baiyang Pharmaceutical, Baiyang Investment, Baiyang Yiren and Baiyang Kanghe in the controlling shareholder Baiyang GroupThe equity, which holds a total of 60.199%of the equity of Baiyang Pharmaceutical, has become its controlling shareholder.The transaction price was 880 million yuan, of which Baiyang Pharmaceutical, Baiyang Investment, and Baiyang Yiren and Baiyang Kanghes evaluation rates reached 249.68%, 308.02%, 487.95%, and 1708.03%, respectively.
Baiyang Pharmaceutical said that through this transaction, the company obtained the support series of Baiyang Pharmaceuticals in the field of Chinese medicine, dizopicon, diopizer in the field of slow -controlling agent,A variety of advantageous products such as Selackerbu are a powerful supplement to the companys existing products.
The net profit of the first three quarters of revenue
Public information shows that Best Medicine is in the pharmaceutical circulation industryThe main business covers three sections: brand operation, wholesale distribution and retail. Among them, brand operations are the companys core business.Benefiting from the influence of the reform of medical policy reforms such as the continuous advancement of the volume procurement and accelerating the approval of new drugs, the companys core brand operation business has maintained a high prosperity.
In June 2021, Baiyang Pharmaceutical landed on the GEM.From 2016 to 2018 before listing, the companys performance increased steadily. In 2019, income increased income and continued until the first half of 2020.Baiyang Pharmaceutical said that the sales of Diqiao series with higher gross profit margins in the first half of 2020 declined significantly, while product sales revenue with relatively low gross profit margin increased, which increased the current net profit.However, in 2020, the companys operating income and net profit resumed double increases, with 5.879 billion yuan and 273 million yuan, respectively.
Since its listing in 2021, Baiyang Pharmaceuticals performance has achieved double increase for three consecutive years.
财报显示，2021年—2023年，公司的营收分别为70.52亿元、75.1亿元、75.64亿元，同比增速分别为19.94%、6.5%、0.72%, the growth rate slowed down; net profit was 423 million yuan, 502 million yuan, and 656 million yuan, respectively, a year -on -year increase of 55.04%, 19.08%, and 29.55%.
From January to September 2024, Baiyang Pharmaceuticals revenue achieved revenue of 6.144 billion yuan, an increase of 2.65%year -on -year; net profit was 641 million yuan, a year -on -year increase of 17.42%.
Baiyang Pharmaceutical said that the growth of the companys net profit is mainly contributed by the brand operation business.In the first three quarters, Baiyangs core business brand operation business realized operating income of 4.133 billion yuan, an increase of 15.48%year -on -year.100 million yuan, an increase of 19.26%year -on -year, and 91.93%of gross profit.
Different from the growth of brand operations, Baiyang Medicines wholesale distribution business achieved operating income of 1.703 billion yuan in the first three quarters, a year -on -year decrease of 19.38%; the retail business achieved operating income of 289 million yuan, whichA year -on -year increase of 8.56%.
